Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization,is it the prime time for unresectable hepatocellular carcinoma?  

作　　者：Natalia Centrone Pedro Luiz Serrano Uson Junior 

机构地区：[1]Center for Personalized Medicine,Hospital Israelita Albert Einstein,Sao Paulo 05651-901,Brazil

出　　处：《World Journal of Gastrointestinal Oncology》2024年第12期4753-4756,共4页世界胃肠肿瘤学杂志（英文）

摘　　要：Hepatocellular carcinoma(HCC)is a lethal disease and unfortunately,most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor.For patients with initially unresectable HCC(uHCC),transarterial chemoembolization(TACE)was the mainstream treatment.Lately,the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC.In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients,and highlight future advances in the field.

关 键 词：Hepatocellular carcinoma Liver cancer Lenvatinib Immunotherapy Checkpoint inhibitors 

分 类 号：R735.7[医药卫生—肿瘤]